leader
رونق تولید
Today : Monday Nov 25 2024
  • Sep 27 2023 - 13:16
  • 310
  • Study time : 3 minute(s)
Dehghani emphasized in "Iran Pharma"

The necessity of adopting macro policies to support knowledge-based pharmaceutical companies

Vice President of Science, Technology and Knowledge-Based Economy, while attending the 8th Iran Pharma Exhibition, visited the capabilities of knowledge-based pharmaceutical companies and had a conversation with the industry's activists.

According to the Communication and Information Center in the Vice Presidency of Science, Technology and Knowledge-Based Economy, Ruhollah Dehghani, on the sidelines of his visit to the knowledge-based companies located in the 8th Iran Pharma Exhibition, said: an energetic and dynamic exhibition with the participation of the powerful pharmaceutical companies of Iran and other countries. We see that it shows the high capacity of this industry in creating employment, economic prosperity and creating health.

He added: A variety of pharmaceutical companies from the field of equipment and machinery for processing, production and packaging to drug formulation and engineering have gathered in this exhibition to once again display the technological and innovative capabilities of Iran in the pharmaceutical industry and economy. In addition to domestic companies, foreign companies from 30 countries are also present at the exhibition and have shared their experiences and products and exposed them to those interested and active in the ecosystem of drug technology and innovation.

The head of the National Elites Foundation stated: The progress of the country's pharmaceutical industry is promising, and this increasing progress and the fact that Iran's pharmaceutical industry has serious things to say at the international level can be clearly felt in this exhibition.

He considered new knowledge-based companies in the pharmaceutical industry to be the basis for connecting innovation with the body of the pharmaceutical industry and said: one of the industries in which small and medium-sized companies have formed well and found their role is the pharmaceutical field. These companies can play the role of a link between the innovative sector and the large pharmaceutical industry market.

Referring to the role of holding promotional events and sharing technological and innovative achievements in discovering new opportunities for cooperation and the prosperity of the knowledge-based economy in the field of health, the vice president of science, technology and knowledge-based economy added: these events help to discover new markets and lead to the growth of the economy of this field. The country's health and pharmaceutical industry has now reached significant maturity and consistency, and this issue requires special attention, care and attention to this field. If there is a careful, macro-policy-based and forward-looking look at the industry, we will soon be on the path to globalization.

He stated that in the field of drug pricing and support for domestically produced drugs, there should be a macro-policy, and he continued: Pricing policy is one of the decisive and key points in the field of medicine, and moving in the right direction is of crucial importance for this. It is an industry and should be taken seriously. When a medicine is imported with a foreign currency price, the country should accept to buy domestically produced medicine with indigenous technology and quality equal to the imported sample that is based on real research and development at least 70% to 80% of the price of the foreign sample. This policy should last for at least four years so that a company that tries to make an imported drug based on local know-how can stand on its own feet. On the other hand, the country's insurance system should also try to get the medicine to the final consumer at a reasonable price.

Referring to the need to apply policies to support the country's pharmaceutical industry, Dehghani said: this policy at the macro level can result in two things; First, it blocks the path of foreign exchange and the country will be able to produce a wide range of medicines that lead to the outflow of foreign exchange capital, domestically and relying on local technology, which, while maintaining domestic capital, will make the country resistant to problems such as sanctions or lack of certain drugs will result.

It should be noted that the 8th International Exhibition of Medicines and Related Industries organized by the Syndicate of Human Pharmaceutical Industry Owners of Iran started today and until the 7th of October in Imam Khomeini Mosque (RA) in Tehran, it introduces the achievements and capabilities of domestic and foreign pharmaceutical industry activists.

 

  • News group : NEWS,Slider,اخبار معاونت ها و مراکز,Headquarters,Communication & Information Center,Knowledge-based Institutions & Companies Center,Deputy for Technology Innovation & Commercialization Develop,Department of STI Policy & Evaluation,Deputy for Management Development & Resources ,International Affairs & Technological Exchange Center,Strategic Technology Development Center
  • News code : 93981
keywords

There are 0 comment(s) for this article

comment

Enter the text inside the security image :

Enter the text inside the security image *

شخصی سازی

انتخاب رنگ

اندازه فونت